



Sensus Healthcare



INVESTOR OVERVIEW

NASDAQ: SRTS

September 2018



Safe Harbor Statement

Forward-Looking Statements

This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this presentation, as a result of, among others, the factors described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission (including the prospectus filed by Sensus Healthcare on June 3, 2016).

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

About Sensus Healthcare

- Sensus Healthcare is an innovative medical device company
 - Founded in 2010, revenue beginning in 2011
 - Sensus is committed to the **non-invasive & cost-effective** treatment of two main conditions: Non-Melanoma Skin Cancer and Keloids
- Technology Disruptor: low dose energy x-ray therapy a **popular choice** for a growing patient population
- IPO in June 2016, traded on NASDAQ (SRTS)
- FDA clearance, CE mark and multiple regulatory clearances worldwide
 - **350+** installations in **16** countries; **1000s** of patients treated



Investment Highlights

- Safe, effective, patented and reimbursed, offering multiple benefits:
 - **Patient benefits:** Excellent clinical outcomes and superior aesthetics
 - **Physician benefits:** Products build practices and improve efficiencies, retain patients and increase the number of visits; excellent ROI
 - **Payor benefits:** Usually less costly than Mohs since no reconstructive or wound care costs
- Large U.S. market with OUS and pipeline opportunities
 - Direct sales in U.S., distribution agreement in China and other countries
 - Targeting additional clearances in Latin American and Asian countries
 - Plans to broaden SRT indications to include **psoriasis** and to introduce **intraoperative radiation therapy (IORT)** for breast and other cancers
 - Introduction of cutting-edge aesthetic lasers directed to existing dermatology customer base
- A clearly-defined customer base to treat a rapidly-growing patient population, both in the U.S. and OUS
- Over **39%** year over year revenue growth to **\$20.6M** in 2017, and a 29% increase to \$12.0 million for the first half of 2018; **mid-to-high-60s** gross margin
- Strong balance sheet, with **\$8.0M** cash, cash equivalents and investments and no long-term debt as of June 30, 2018
- Executive team has strong record with capital equipment models

Our Technology

Superficial Radiation Therapy(SRT)

- Low-energy Photon Radiotherapy
 - 100% of the energy is focused directly on the surface of the skin using customized proprietary applicators
 - Penetrates no deeper than 5mm below skin's surface
 - Covered by IP portfolio
- Compact, 30" x 30" footprint
 - 2 models: SRT-100™ and SRT-100 Vision™
- Proven award-winning technology
- Scalable platform – new future indications




SRT: For Non-Melanoma Skin Cancer (NMSC)



Skin Cancer: Large & Growing Market


- Fastest growing cancer indication with 6M+ new cases/year by 2020
- 4X greater than all other cancers combined
- 80% of skin cancers occur on head/neck regions
- 31% of skin cancers on tip of nose

Estimated Cancer Incidence Rates for 2011



Source: American Cancer Society; Cancer Facts and Figures 2011


% of Non-Melanoma Skin Cancer by Location



Skin Cancer: Treatment Challenges

Mohs Surgery

- Original “Gold Standard” for NMSC treatment
 - Invasive and complicated
 - Requires a highly-skilled surgeon
 - Time-consuming for physician
 - Very expensive to healthcare system
- Often results in **poor cosmetic outcomes** in facial areas, forcing patients to consider reconstructive surgery and wound care
- Pre-existing conditions (diabetes, heart conditions) have **increased risks** for healing
- Lower limb (shin) & scalp are **hard-to-heal** areas post surgery



SRT: Superior Clinical Outcomes

SRT for NMSC

- Same cure rates as Mohs, supported by clinical studies
- Non-invasive, no lifestyle impact
- No anesthesia, no cutting, no pain
- No comorbidity limitations
- Ideal to treat lower limb, scalp, and other challenging sites
- Non-surgeon can keep patient and cross-sell (multiple visits)
- Saves costs to the healthcare system



01/14/08
300 cGy



01/28/08
2,000 cGy



02/11/08
FINAL TREATMENT



04/02/08
APPROX 3.5 MONTHS AFTER FINAL TREATMENT



02/11/08
250 cGy



02/21/08
2,000 cGy



03/06/08
4000 cGy FINAL TX
1000 cGy 1st visit, 2nd visit, 3rd visit, 4th visit, 5th visit, 6th visit, 7th visit, 8th visit, 9th visit, 10th visit, 11th visit, 12th visit, 13th visit, 14th visit, 15th visit, 16th visit, 17th visit, 18th visit, 19th visit, 20th visit, 21st visit, 22nd visit, 23rd visit, 24th visit, 25th visit, 26th visit, 27th visit, 28th visit, 29th visit, 30th visit, 31st visit, 32nd visit, 33rd visit, 34th visit, 35th visit, 36th visit, 37th visit, 38th visit, 39th visit, 40th visit, 41st visit, 42nd visit, 43rd visit, 44th visit, 45th visit, 46th visit, 47th visit, 48th visit, 49th visit, 50th visit, 51st visit, 52nd visit, 53rd visit, 54th visit, 55th visit, 56th visit, 57th visit, 58th visit, 59th visit, 60th visit, 61st visit, 62nd visit, 63rd visit, 64th visit, 65th visit, 66th visit, 67th visit, 68th visit, 69th visit, 70th visit, 71st visit, 72nd visit, 73rd visit, 74th visit, 75th visit, 76th visit, 77th visit, 78th visit, 79th visit, 80th visit, 81st visit, 82nd visit, 83rd visit, 84th visit, 85th visit, 86th visit, 87th visit, 88th visit, 89th visit, 90th visit, 91st visit, 92nd visit, 93rd visit, 94th visit, 95th visit, 96th visit, 97th visit, 98th visit, 99th visit, 100th visit




06/05/08
APPROX 5.5 MONTH AFTER FINAL TX
1000 cGy 1st visit, 2nd visit, 3rd visit, 4th visit, 5th visit, 6th visit, 7th visit, 8th visit, 9th visit, 10th visit, 11th visit, 12th visit, 13th visit, 14th visit, 15th visit, 16th visit, 17th visit, 18th visit, 19th visit, 20th visit, 21st visit, 22nd visit, 23rd visit, 24th visit, 25th visit, 26th visit, 27th visit, 28th visit, 29th visit, 30th visit, 31st visit, 32nd visit, 33rd visit, 34th visit, 35th visit, 36th visit, 37th visit, 38th visit, 39th visit, 40th visit, 41st visit, 42nd visit, 43rd visit, 44th visit, 45th visit, 46th visit, 47th visit, 48th visit, 49th visit, 50th visit, 51st visit, 52nd visit, 53rd visit, 54th visit, 55th visit, 56th visit, 57th visit, 58th visit, 59th visit, 60th visit, 61st visit, 62nd visit, 63rd visit, 64th visit, 65th visit, 66th visit, 67th visit, 68th visit, 69th visit, 70th visit, 71st visit, 72nd visit, 73rd visit, 74th visit, 75th visit, 76th visit, 77th visit, 78th visit, 79th visit, 80th visit, 81st visit, 82nd visit, 83rd visit, 84th visit, 85th visit, 86th visit, 87th visit, 88th visit, 89th visit, 90th visit, 91st visit, 92nd visit, 93rd visit, 94th visit, 95th visit, 96th visit, 97th visit, 98th visit, 99th visit, 100th visit

Skin Cancer Clinical Studies

- SRT is proven to be safe with a comparable cure rate to Mohs surgery
- Cognetta et al (2012) conducted a retrospective analysis on 1,715 confirmed primary cutaneous basal cell carcinoma (“BCC”) and squamous cell carcinoma (“SCC”) treated with SRT between 2000 and 2010
- Cumulative recurrence rates of all tumors at 2 and 5 years were 1.9% and 5.0%, respectively


Author	N	Treatment	FUP	Local Control
Cognetta A. (2012)	1,715	SRT	5 years	95% (BCC & SCC)
Silverman (1992)	1,288	SRT		95.6% if 1cm or less
Klaus-Werner Schulte (2005)	1,267	SRT	5 years	94.9% (BCC & SCC)
Hernandez – Machin B (2007)	710	SRT	5 years	94.4% BCC; 92.7% SCC
GEC (1989)	1,676	RT	Min 2 years	95% if primary treatment; 88% if recurrence

SRT: For Treatment of Keloids



What are Keloids?

- A keloid is an area of irregular fibrous tissue formed at the site of a scar or injury
- NIH estimates over 11 million individuals worldwide living with keloid scars
 - Genetic predisposition to having keloids: African Americans, Latinos, Asians
 - Incidence is estimated to be between 4.5% to 16% among ethnic skin types



Source: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225895/>

Journal of Family Practice (May 2013); Keloids: Which treatment is best for your patient?

Keloids: Treatment Challenges

- Surgery and other current treatment methods may reduce the size of the keloid, but are not a permanent solution
- Recurrence rates of keloids are very high, at up to 90%
- Most patients with keloids are simply told by their doctors: *"Sorry, there is no remedy..."*
- Expensive treatments that are usually paid out-of-pocket by the patient
- Insurance covers treatment only if **combined with SRT**



Before:



During:



Immediate Post Surgery:




The Result:



Keloids Before/After SRT Treatment



- Recent clinical study on keloid surgery followed by with SRT had **100% success rate**
- Approximately **70+ Sensus customer sites** are treating keloids




Keloid Clinical Studies

- SRT is proven to be safe, and **the most effective treatment** in reducing recurrence of keloids when combined with excision surgery

Study	Results
Chaudhry et al (1994)	2.8% recurrence rate with a mean follow-up period of 5.6 years
Jones et al (2015)	100% cure rate
Doombos et al (1990)	90% control rate
Klumpar et al (1994)	Control rates of 72% to 92%
Kovalic et al (1989)	73% control rate; decrease in recurrence rate by 50%
Mitsubishi et al (1995)	76% control rate
Ragoowansi et al (2003)	9% recurrence rate at 1 year; 16% recurrence rate at 5 years
Sallstrom et al (1989)	“Good” or “excellent” results were observed in 92% of patients

SRT Vision™:


The World's First Image-Guided SRT



The SRT-100 Vision™ (IGSRT)


Unique, image-guided therapy: “*See & treat*”

- **World’s first** IGSRT (Image-Guided SRT) designed to:
 - Track disease progression
 - Plan treatment
 - Guide therapy
 - Administer radiation
 - Evaluate treatment
- State-of-the-art platform ideal for teaching/research hospitals, large community hospitals
- FDA 510(k)-cleared, offers advanced workflow and safety; comprehensive enterprise integration



Skin Cancer – Captured at 40 MHz

Normal Skin



Skin Cancer




Image-Guided Treatment Planning

First Name: Amanda
Last Name: Bell
Accession ID: 561927555
Therapy ID: 1

Background & Prognosis:
 BCC on upper right torso. Patient exhibited th...
 were treated with SRT with no visible recurrence

List of Sessions

No.	Time Stamp	kV	mA
1	04/20/2015 16:48:58	50	10
2	04/20/2015 16:50:11	50	10
3	04/20/2015 16:55:20	50	10
4	04/20/2015 16:56:22	50	10

Dosimetry
☒ Auto ☐ Manual
 cGy/Min Lead Shield Correction Fx

Ultrasound Photo 1 **Ultrasound Photo 2**
 Photo 1 **Photo 2**
 Export / Print ☐ ☐

Lesion Topography
 Sensus Healthcare
 4/21/2015 17:57:13
 Probe: B12.1 X 13mm 20MHz
 Gain Preset: 3
 AVG Gain: 22
 ROI = 0.32mm²
 1.19 mm
 2.71 mm

Treatment Parameters:
 BED: 66
 TDF: 97
 DOSE [cGy]: 263.2
 ENERGY: 50
 TIME: 0.40
 TOTAL FRACTIONS: 20
 Current APPLICATOR # 10
 Diameter: 5.0 cm
 SSD: 15 cm
 FRACTIONS PER WEEK: 1 2 3 4 5
 Acquire U/S
 Capture
 LOAD FOR TREATMENT
 Patient Tx Ready

Image-Guided Treatment Planning and Dosimetry

The SRT Market:

Growth Opportunity
with Sensus Healthcare



Addressable Market

Channel	Total Potential Sites	High Probability Sites ⁽¹⁾	Early Adopters ⁽²⁾	Installed Sites	% Installed of total potential Sites
Mohs Surgeons	1,000	1,500	400	100	10%
Dermatologists	14,000	7,500	5,000	125	>1%
Plastic Surgeons	6,500	2,500	500	10	>1%
Radiation Oncologists	5,500	2,000	500	2	>1%
Hospitals and Surgery Centers	1,400	500	100	48	3.4%
International Hospitals	17,800	4,000	1,000	50	>1%
Total	46,200	18,000	7,500	335	>1%


(1) Sites with capital resources and patient volume to justify capital equipment expense.

(2) High probability sites with physicians and/or patients looking for treatment alternatives.




SCULPTURA

IORT for Additional
Indications




Sculptura®

Robotic Intra-Operative Radio-Therapy System



Beam Sculpturing C_w-Mo Morpheus™ X-Ray Source


- State-of-the-art beam and dose sculpturing in 360°
- Full flexibility in Morpheus™ target design for beam resolution and power
- Patented proprietary technology – designed and owned by Sensus Healthcare, Inc.



Radial Position 2.5 mm

Radial Position 5.0 mm

Radial Position 7.5 mm




Axial
Beam Position



Equidistant
Beam Position




Distal
Beam Position



Aesthetic Dermatology

Cutting-edge Laser
Technology



Sensus LASER SYSTEMS

- Tattoo Removal
- Hair Removal
- Anti-Aging
- Acne Lesion Correction
- Pigmentation Treatment
- Large Pore Treatment



Sensus LASER SYSTEMS



CO₂

MAIN APPLICATION:

Surgical applications requiring ablation vaporization, excision, incision, and coagulation of soft tissue.

Wave Length (nm): 10.6

Aiming Beam: 630nm red dioxide laser (5mW)

Pulse Duration:
Pulse 0.05 - 1s
Super Pulse 0.01 - 1s

Controlled Working Modes:
Continuous Pulse
Super Pulse
Pulse, Scanner

Spot Size (mm): <0.5

Max Power Output: 30W

Cooling System:
Water Cooling System

Dimensions(cm):
56x50x144

Weight (kg): 46



IPL

MAIN APPLICATION:

Hair removal, skin rejuvenation, vascular and pigmented lesions.

Wave Length (nm):
560-1200
700-1200
400-700
525-1200

Fluence (J/cm²): 3-36

Pulse Duration (ms):
4-512

Frequency (Hz): 1, 1/2, 1/3

Spot Size (mm): 10.88 x 45.8

Cooling System:
Integrated Pyroelectric
Contact Cooling

Dimensions(cm):
48x38x102

Weight (kg): 46



ND:YAG

MAIN APPLICATION:

Tattoo removal, pigmented lesion treatment including Nevus of Ota, chloasma, age spots, freckles, and sun spots.

Wave Length (nm):
1064/532

Fluence (J/cm²): 1-14

Pulse Duration (ms): <10

Frequency (Hz): 1, 2, 4, 10

Spot Size (mm): 2, 3, 4, 6

Aiming Beam:
Red LD

Dimensions(cm):
80x43x85

Weight (kg): 98

Our Financial Model

- One-time sale of capital equipment with annual service contract
 - Lack of consumables aligns the product economic model with the evolving reimbursement environment
- Recurring revenue from service contracts
- Investing in Sales and Marketing with the hiring of additional direct sales representatives
- Investing in R&D to expand the indications for SRT and develop new products for existing and new markets, including IORT
- Investing in direct-to-consumer programs in conjunction with physicians, to raise awareness of SRT treatment for keloids

2018-2019 Growth Strategies

Expand U.S. Operations

- Expanded sales force in 2017; more expansion in 2018 and 2019

Expand International Market

- Largest current international market is China
- Step up marketing in Mexican following clearance in Oct. 2017 for NMSC and keloids
- Additional foreign markets including Israel, Poland, Korea, Thailand, Vietnam with support from CellMark Medical to expand global reach

Increase Awareness of SRT Treatment for Keloids

- Keloids market is an even bigger opportunity than NMSC
- Obtained CFDA clearance for keloids in China in July 2017; promoted SRT for keloids at October DASIL conference in Shanghai
- Sponsored 2nd Annual International Keloid Conference in NYC in November 2017

Product Roadmap

- Lower energy options (Grenz Rays) on recently released SRT-100+ for psoriasis and other inflammatory skin conditions; clinical studies ongoing
- IORT development for breast and other cancers; FDA clearance expected by end of Q4 2018

Management Team

Joseph C. Sardano, President and CEO

- Elscint Medical Imaging – Vice President driving Sales & Marketing, led to joint acquisition between General Electric and Picker Medical (Philips) Imaging totaling approximately \$650M.
- GE Healthcare – GSM, Functional Imaging (Positron Emission Tomography) imaging group, capturing #1 market share as well as reaching \$320 million in sales within the first 24 months.
- CTI Molecular Imaging/Siemens Medical Imaging – Sr. Vice President, Molecular Imaging. Built top caliber team capturing 35% market share in one year. Accelerated put-call option with Siemens resulting in an acquisition valued at \$2.2 billion.

Kal Fishman, CTO

- GE Healthcare – lead Engineering Team in fusion software development for PET/CT product
- Elscint Medical Imaging – Invented eNTEGRA PE™ Pocket PC™ workstation
- CTI Molecular Imaging – Director Sales & Marketing

Arthur Levine, CFO

- IVAX Diagnostics – CFO
- Trade Street Residential – CAO
- Ernst & Young – Senior Manager
- Wharton, CPA

Isabelle Raymond, Ph.D, VP Clinical Development

- Eleltis – Director, Scientific & Medical Affairs
- Valeant Pharmaceuticals – Sr. Scientific Medical Liaison
- EternoGen – Director of Medical Affairs

Richard Golin, EVP International Sales

- CTI Molecular Imaging – VP Sales
- Toshiba Medical – Regional Sales Manager
- Hologic – Director, Sales
- International Medical Technologies – President
- Xoft – VP Sales

Steve Cohen, EVP Strategic Initiatives & Dermatology

- Technicare (J&J) – Regional Sales Manager
- Don L Leasing – CEO
- Xoft – Regional Sales Manager
- Dasonics – Regional Sales Manager

Rita Gable, VP of Sales, Oncology

- IBA – Strategic Account Manager
- Tomotherapy – Account Manager
- General Electric Healthcare – CVCT Product Specialist

Board of Directors and Medical Advisory Board

Board of Directors

- Joseph Sardano, CEO
- John Heinrich, PhD
- William McCall
- Sam O'Rear
- Anthony Petrelli

Medical Advisory Board

Dermatology

- Clay Cockerell, MD – Texas
- Mark Nestor, MD, PhD – Florida
- Armand Cognetta Jr., MD – Florida
- Gary Monheit, MD – Alabama
- Angela Abbatecola, MD, PhD – Italy
- William Roth, MD – Florida
- David Goldberg, MD, JD – New Jersey
- Michael Beer, MD – California
- Brian Berman, MD, PhD – Florida
- Michael Gold, MD – Tennessee

Radiation Oncology

- Kevin Schewe, MD - Colorado

Summary

- ✓ Disruptive patented technology adaptable to other skin conditions and cancers
- ✓ Large, growing, underserved market
- ✓ Significant advantage to patients compared to existing treatments
- ✓ Improved physician productivity and economics
- ✓ Technology transitions well into the new healthcare system: high efficacy and cost effective



SRT-100 Vision™